SOPHiA GENETICS (NASDAQ:SOPH) Insider Well Daan Van Sells 6,168 Shares of Company Stock

Key Points

• Insider sale: Well Daan Van sold 6,168 SOPHiA GENETICS shares for $50,084 at an average price of $8.12, reducing his position by 1.82% to 332,716 shares. The transaction was made under a pre-arranged Rule 10b5-1 plan to cover tax obligations tied to vested equity awards.
• Stock and financial performance: SOPH shares recently traded at $7.15, with a 12-month range of $3.75 to $8.98. The company reported a quarterly loss of $0.26 per share, missing estimates, although revenue of $23.31 million exceeded expectations.
• Analyst outlook: Analysts have a consensus “Hold” rating and a $10.00 price target, with some firms assigning “Buy” ratings and raising targets as high as $14.00.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Well Van sold 6,168 shares of the firm's stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $8.12, for a total value of $50,084.16. Following the completion of the transaction, the insider owned 332,716 shares in the company, valued at approximately $2,701,653.92. This trade represents a 1.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Well Daan Van also recently made the following trade(s):

• On Friday, September 11th, Well Van sold 6,168 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.63, for a total value of $47,061.84.

SOPHiA GENETICS Price Performance

Shares of SOPH traded down $0.23 during trading hours on Wednesday, hitting $7.15. 432,750 shares of the stock were exchanged, compared to its average volume of 308,157. The stock's 50-day moving average price is $7.82 and its two-hundred day moving average price is $6.12. SOPHiA GENETICS SA has a 12-month low of $3.75 and a 12-month high of $8.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The company has a market cap of $599.81 million, a price-to-earnings ratio of -6.22 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million during the quarter, compared to analysts' expectations of $21.72 million. Research analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Brokerages reportedly have a consensus price target of $10.00 for SOPHiA GENETICS, suggesting potential upside from recent trading levels if the company meets analyst expectations. SOPHiA GENETICS SA Stock Has Consensus Target Price of $10.00 According to Brokerages
• Neutral Sentiment: A comparison article examined SOPHiA GENETICS against Weave Communications, but the item did not identify a specific new company development or change to SOPH’s outlook. Critical Comparison: Weave Communications vs. SOPHiA GENETICS
• Negative Sentiment: Company insiders collectively sold approximately 82,298 shares worth $668,827, including sales by Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma and other executives. The transactions reduced their individual holdings by roughly 0.15% to 3.55%, creating near-term selling pressure and potentially weighing on investor sentiment. However, all reported sales were pre-arranged and explicitly made to satisfy tax obligations rather than indicating discretionary selling. SEC insider transaction filing

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on SOPH shares. Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. HC Wainwright raised their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, BTIG Research upped their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, SOPHiA GENETICS currently has an average rating of "Hold" and a consensus target price of $10.00.

Hedge Funds Weigh In On SOPHiA GENETICS

Institutional investors have recently bought and sold shares of the company. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS in the 2nd quarter valued at approximately $9,809,000. Hodges Capital Management Inc. purchased a new position in SOPHiA GENETICS in the first quarter worth approximately $2,157,000. Sei Investments Co. purchased a new stake in SOPHiA GENETICS in the first quarter valued at $1,772,000. Maven Securities LTD acquired a new position in shares of SOPHiA GENETICS in the 2nd quarter valued at $866,000. Finally, Hennion & Walsh Asset Management Inc. purchased a new position in shares of SOPHiA GENETICS during the 2nd quarter worth $567,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company's principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.